Harvard Business Review studies an alliance between Quintiles and Solvay. more...

The big CRO discusses the growing importance of patients’ perspectives. more...

The CRO is loved by sites and has ex-FDA scientists in top executive positions. more...

Bad news and good from the troubled CRO. more...

The CRO announces some restructuring of business development. more...

Gradual improvement, not rapid expansion, has been the recent story. more...

The top contract research organization just expanded in Edinburgh. Next up: Singapore. more...

The research firm’s forecast for CROs looks good, though there are a few caveats. more...

A conversation with Jules Mitchel of Target Health more...

ARG has become the first U.S. partner—a Europe-based cluster of small CROs that work together on global trials. A what? We explain… more...

MDS never quite recovered from an FDA audit, and is now trying to sell MDS Pharma Services. more...

A Memphis-based oncologist network is automating study start-up with its own document management system. more...

San Diego-based Synteract has its eye on global expansion and an offering for financiers. more...

Despite all the hype about global trials in China, two industry veterans say the challenges remain significant. more...

Why some CROs won’t say exactly how many feet they have on the ground in India. more...

INC and MDS Pharma talk to ClinPage about their upcoming nuptials. more...